Lonza acquires Cambrex Bio-Businesses

Published: 8-Feb-2007

Lonza has announced that it has completed the acquisition of the Research Bioproducts business and the Microbial Biopharmaceutical business of US company Cambrex.


Lonza has announced that it has completed the acquisition of the Research Bioproducts business and the Microbial Biopharmaceutical business of US company Cambrex.

The Microbial Biopharmaceutical business will be integrated into the existing Lonza Biopharmaceuticals. The Research BioProducts will be positioned as a stand-alone business unit and renamed Lonza Bioscience.

“The closing of the Cambrex Bio-Businesses acquisitions marks an important milestone within Lonza's transformation into a focused life sciences company,” Said Stefan Borgas, ceo of Lonza.

  • Companies:
  • Lonza
See more

You may also like

Ingredients

Arxada completes first-ever merger deal since split from Lonza Group

Read more
Chemicals company successfully merges with microbial solutions provider Troy Corporation

Trending Articles

  1. Seen snaps up former Ulta Beauty boss as Chief Marketing Officer Linh Peters previously served as Head of Loyalty Marketing and Strategy at Ulta Beauty, overseeing the US beauty retailer’s loyalty programme and personalisation engine
  2. L'Oréal, LVMH and Luxottica named preferred buyers of Giorgio Armani empire The late Italian fashion designer has given purchasing priority to L'Oréal, along with LVMH, owned by the world’s richest man, Arnault Bernard, and eyewear brand Luxottica
  3. Glossier names Colin Walsh CEO as it aims to become ‘a true legacy brand’ Walsh, who has previously helmed the beauty divisions of Ouai and Procter & Gamble, will join the beauty company in October
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Maison Francis Kurkdjian turns heads with new $28,000 bottle of Baccarat Rouge 540 The fragrance giant has shocked consumers with its latest launch. Only 54 bottles of new Baccarat Rouge 540 Édition Millésime will be created each year, housed in a red crystal bottle with a 24-carat gold cap
  5. La Roche-Posay lands Law Roach for punny partnership marking 50th anniversary The L’Oréal-owned skin care brand has brought in the celebrity stylist alongside a cast of experts and creators for its ‘Brand Name’ Campaign in an attempt to connect with younger generations

Upcoming event

13th Annual Beauty Trends & Innovations Conference

24 September 2025 | London, UK See all

You may also like

Ingredients

Arxada completes first-ever merger deal since split from Lonza Group

Chemicals company successfully merges with microbial solutions provider Troy Corporation
Ingredients

Former Lonza business LSI rebrands as Arxada

LSI launched in July, following its divestment from Lonza, with the announcement that a name change was on the cards
Ingredients

Lonza completes divestment of Specialty Ingredients business

Former supplier to the beauty and personal care industry now a pure-play healthcare company
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Polishing that portfolio: What do ingredient company M&As mean for beauty makers?

With a flurry of new acquisition and divestment announcements making headlines, we discover who in the cosmetic ingredients sector is growing or streamlining their offer
Ingredients

Lonza takes step away from personal care with Specialty Ingredients sale

The chemicals giant has sold the business unit to Bain Capital and Cinven for CHF4.2bn
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Versatile molecules: What are surfactants and how do they work?

Surfactants are arguably the most versatile of all molecules, as Jordan Petkov explains
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

2020's hottest sun protection solutions

While new UV absorbers are a rarity, sunscreen manufacturers can mitigate the harmful effects of the sun through clever use of new and existing ingredients, as John Woodruff reports
Subscribe now